 | CytoDyn: COVID-19 Crunch Time - Seeking Alpha
seekingalpha.com - June 4 at 5:31 PM |
| CytoDyn gives Mulholland permanent CFO job
seekingalpha.com - June 3 at 7:28 AM |
| CytoDyn Inc. 8-K Jun. 2, 2020 5:00 PM - Seeking Alpha
seekingalpha.com - June 2 at 8:19 PM |
 | CytoDyn to Present at Wall Street Reporter’s Livestream Event on June 2, 2020 at 12:30 pm ET / 9:30 am PT - Yahoo Finance
finance.yahoo.com - June 1 at 1:01 PM |
| CytoDyn requests for priority review of Leronlimab BLA for HIV - Seeking Alpha
seekingalpha.com - June 1 at 8:01 AM |
 | CytoDyn to Present at Wall Street Reporter's Livestream Event on June 2, 2020 at 12:30 pm ET / 9:30 am PT - GlobeNewswire
www.globenewswire.com - June 1 at 8:01 AM |
| CytoDyn Files Request With FDA for Priority Review of BLA for First Approval
finance.yahoo.com - June 1 at 8:01 AM |
| CytoDyn to Present at Wall Street Reporter’s Livestream Event on June 2, 2020 at 12:30 pm ET / 9:30 am PT
finance.yahoo.com - June 1 at 8:01 AM |
| CytoDyn to Hold Conference Call to Provide Updates on COVID-19 (Phase 2, 3 & eIND), Cancer (mTNBC, Phase 2 for 22 Solid Tumor Cancers), HIV (BLA, Monotherapy), NASH, GvHD and MS - Yahoo Finance
finance.yahoo.com - May 23 at 3:15 AM |
| CytoDyn to Hold Conference Call to Provide Updates on COVID-19 (Phase 2, 3 & eIND), Cancer (mTNBC, Phase 2 for 22 Solid Tumor Cancers), HIV (BLA, Monotherapy), NASH, GvHD and MS - GlobeNewswire
www.globenewswire.com - May 22 at 10:01 PM |
|
| CytoDyn to Hold Conference Call to Provide Updates on COVID-19 (Phase 2, 3 & eIND), Cancer (mTNBC, Phase 2 for 22 Solid Tumor Cancers), HIV (BLA, Monotherapy), NASH, GvHD and MS
finance.yahoo.com - May 22 at 10:01 PM |
| CytoDyn and the Mexican National Institutes of Health Participate in a Collaborative Study of Leronlimab for the Treatment of Severe/Critical COVID-19 Population - Yahoo Finance
finance.yahoo.com - May 19 at 10:39 PM |
| CytoDyn and the Mexican National Institutes of Health Participate in a Collaborative Study of Leronlimab for the Treatment of Severe/Critical COVID-19 Population - GlobeNewswire
www.globenewswire.com - May 19 at 7:30 AM |
| CytoDyn and the Mexican National Institutes of Health Participate in a Collaborative Study of Leronlimab for the Treatment of Severe/Critical COVID-19 Population
finance.yahoo.com - May 19 at 7:30 AM |
| CytoDyn to compare leronlimab to remdesivir in COVID-19 - Seeking Alpha
seekingalpha.com - May 18 at 1:20 PM |
| CytoDyn to Prepare a Phase 3 Protocol to Submit to the FDA for a Three-Arm Comparative and Combination Trial of Leronlimab and Remdesivir - Yahoo Finance
finance.yahoo.com - May 18 at 1:20 PM |
| CytoDyn to Prepare a Phase 3 Protocol to Submit to the FDA for a Three-Arm Comparative and Combination Trial of Leronlimab and Remdesivir
finance.yahoo.com - May 18 at 8:18 AM |
| CytoDyn to Offer No-Cost Exploratory Laboratory Testing for Childhood Inflammatory Disease Associated with COVID-19 - Yahoo Finance
finance.yahoo.com - May 15 at 9:57 AM |
| CytoDyn to Offer No-Cost Exploratory Laboratory Testing for Childhood Inflammatory Disease Associated with COVID-19
finance.yahoo.com - May 15 at 9:57 AM |
| CytoDyn (CYDY) to Report Q4 Earnings: What's in the Cards? - Yahoo Finance
finance.yahoo.com - May 14 at 6:28 PM |
| CytoDyn completes rolling U.S. application for leronlimab in HIV - Seeking Alpha
seekingalpha.com - May 14 at 1:27 PM |
 | CytoDyn (CYDY) to Report Q4 Earnings: What's in the Cards?
www.nasdaq.com - May 13 at 5:25 PM |
| CytoDyn Completed Submission of All Remaining Parts of Biologics License Application (“BLA”) on May 11, 2020 - GlobeNewswire
www.globenewswire.com - May 13 at 7:24 AM |
| CytoDyn Completed Submission of All Remaining Parts of Biologics License Application (“BLA”) on May 11, 2020
finance.yahoo.com - May 13 at 7:24 AM |
|
| CytoDyn to Present at Wall Street Reporter's NEXT SUPERSTOCK Livestream Event on May 13, 2020 at 12:30 pm ET / 9:30 am PT - GlobeNewswire
www.globenewswire.com - May 11 at 5:53 PM |
| CytoDyn to Present at Wall Street Reporter’s NEXT SUPERSTOCK Livestream Event on May 13, 2020 at 12:30 pm ET / 9:30 am PT
finance.yahoo.com - May 11 at 7:14 AM |
| CytoDyn: Matching Leronlimab Up Against Other COVID-19 Therapeutics - Seeking Alpha
seekingalpha.com - May 11 at 2:14 AM |
| CytoDyn Clarifies Status of Biologics License Application - Yahoo Finance
finance.yahoo.com - May 8 at 11:30 PM |
 | Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of CytoDyn Inc. (CYDY) on Behalf of Investors - Business Wire
www.businesswire.com - May 8 at 6:29 PM |
| Federman & Sherwood Investigates CytoDyn Inc. for Possible Violations of Federal Securities Laws - Yahoo Finance
finance.yahoo.com - May 8 at 6:29 PM |
| SHAREHOLDER ALERT: Investigation of CytoDyn Announced by Holzer & Holzer, LLC
finance.yahoo.com - May 8 at 6:29 PM |
| Federman & Sherwood Investigates CytoDyn Inc. for Possible Violations of Federal Securities Laws
finance.yahoo.com - May 8 at 6:29 PM |
| INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of CytoDyn Inc. (CYDY) on Behalf of Investors
finance.yahoo.com - May 8 at 6:29 PM |
| The Law Offices of Frank R. Cruz Announces Investigation on Behalf of CytoDyn Inc. Investors (CYDY)
finance.yahoo.com - May 8 at 6:29 PM |
| Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of CytoDyn Inc. (CYDY) on Behalf of Investors
finance.yahoo.com - May 8 at 6:29 PM |
| Novant Health Initiates Phase 2b/3 Trial with CytoDyn’s Leronlimab for Severely and Critically Ill COVID-19 Patients
finance.yahoo.com - May 8 at 4:12 AM |
| Novant Health Initiates Phase 2b/3 Trial with CytoDyn's Leronlimab for Severely and Critically Ill COVID-19 Patients - GlobeNewswire
www.globenewswire.com - May 7 at 11:12 PM |
| CytoDyn's Answer To COVID-19 - Seeking Alpha
seekingalpha.com - May 7 at 6:11 PM |
| Manuscript Describes How CytoDyn’s Leronlimab Disrupts CCL5/RANTES-CCR5 Pathway, Thereby Restoring Immune Homeostasis, Reducing Plasma Viral Load, Reversing Hyper Immune Activation and Inflammation in Critical COVID-19 Patients - Yahoo Finance
finance.yahoo.com - May 6 at 2:02 PM |
| Manuscript Describes How CytoDyn's Leronlimab Disrupts CCL5/RANTES-CCR5 Pathway, Thereby Restoring Immune Homeostasis, Reducing Plasma Viral Load, Reversing Hyper Immune Activation and Inflammation in Critical COVID-19 Patients - GlobeNewswire
www.globenewswire.com - May 6 at 4:26 AM |
| Manuscript Describes How CytoDyn’s Leronlimab Disrupts CCL5/RANTES-CCR5 Pathway, Thereby Restoring Immune Homeostasis, Reducing Plasma Viral Load, Reversing Hyper Immune Activation and Inflammation in Critical COVID-19 Patients
finance.yahoo.com - May 6 at 4:26 AM |
 | Ajinomoto Bio-Pharma Services annonce un partenariat de fabrication avec CytoDyn concernant un médicament utilisé dans les essais cliniques contre le COVID-19
www.prnewswire.com - May 5 at 8:27 AM |
| Ajinomoto Bio-Pharma Services gibt Partnerschaft mit CytoDyn für Fertigung von Medikamenten bekannt, die in klinischen Studien zu COVID-19 verwendet werden
www.prnewswire.com - May 5 at 8:27 AM |
| Ajinomoto Bio-Pharma Services Announces Manufacturing Partnership with CytoDyn for Drug Product Used in COVID-19 Clinical Trials - PRNewswire
www.prnewswire.com - May 5 at 8:17 AM |
| “Next Super Stocks” in News: fuboTV (OTC: FUBO) Edgar Bronfman, Jr. Appointed Executive Chairman - CytoDyn (OTC: CYDY) Reports Strong Results From COVID-19 Coronavirus Patients Treated with Leronlimab - NexTech AR Solutions (OTC: NEXCF) Acquires Remote Work/Learning App with Blue Chip Customer Base - Yahoo Finance
finance.yahoo.com - May 4 at 5:15 PM |
| “Next Super Stocks” in News: fuboTV (OTC: FUBO) Edgar Bronfman, Jr. Appointed Executive Chairman - CytoDyn (OTC: CYDY) Reports Strong Results From COVID-19 Coronavirus Patients Treated with Leronlimab - NexTech AR Solutions (OTC: NEXCF) Acquires Remote Work/Learning App with Blue Chip Customer Base
finance.yahoo.com - May 4 at 5:15 PM |
| FDA Approves 54 Emergency INDs for Leronlimab Treatment of Coronavirus – CytoDyn Requests Compassionate Use from FDA for COVID-19 Patients Not Eligible for Participation in Two Ongoing Clinical Trials in U.S. – CytoDyn Targets Enrollment Completion for its 75 Patient, Phase 2 Trial by End of May - GlobeNewswire
www.globenewswire.com - May 4 at 6:36 AM |
| FDA Approves 54 Emergency INDs for Leronlimab Treatment of Coronavirus – CytoDyn Requests Compassionate Use from FDA for COVID-19 Patients Not Eligible for Participation in Two Ongoing Clinical Trials in U.S. – CytoDyn Targets Enrollment Completion for its 75 Patient, Phase 2 Trial by End of May
finance.yahoo.com - May 4 at 6:36 AM |
 | Experimental coronavirus treatment leronlimab resulted in 'remarkable recoveries,' developer says - Fox News
www.foxnews.com - May 1 at 4:38 PM |
| CytoDyn Issues Update On COVID-19 Patients Receiving Leronlimab Under EINDs - Nasdaq
www.nasdaq.com - April 30 at 6:19 PM |
